GLYCOGEN STORAGE DISEASE TYPE I

Glycogen Storage Disease Type I — where the specific gene (G6PC vs. SLC37A4) determines whether the patient faces only metabolic challenges or also develops neutropenia, recurrent infections, and inflammatory bowel disease requiring additional targeted therapy.

Whole genome sequencing distinguishes GSD type Ia (G6PC) from type Ib (SLC37A4) — a critical distinction because type Ib patients develop neutropenia treatable with empagliflozin, a repurposed SGLT2 inhibitor that has transformed type Ib management.

G6PC
SLC37A4

About this condition

Glycogen Storage Disease Type I

Glycogen storage disease type I (GSD-I, von Gierke disease) is an autosomal recessive disorder of glucose metabolism caused by deficiency of either glucose-6-phosphatase-α (type Ia, G6PC gene, chromosome 17q21.31, ~80% of cases) or the glucose-6-phosphate translocase (type Ib, SLC37A4 gene, chromosome 11q23.3, ~20%). Both subtypes prevent the final step of hepatic glycogenolysis and gluconeogenesis — the dephosphorylation of glucose-6-phosphate to free glucose — causing severe fasting hypoglycemia, hepatomegaly, hyperlipidemia, hyperuricemia, and lactic acidosis. GSD-I affects approximately 1 in 100,000 births.

GSD-I presents in infancy with hepatomegaly (massive glycogen accumulation), severe fasting hypoglycemia (symptomatic within 3-4 hours of fasting), lactic acidosis, hyperlipidemia (triglycerides often >1,000 mg/dL), and hyperuricemia. Long-term complications include hepatic adenomas (developing in 50-75% of patients by adulthood, with malignant transformation risk), gout, nephrolithiasis, progressive renal disease, and osteoporosis. Dietary management — continuous glucose supply through frequent meals, uncooked cornstarch (which provides sustained glucose release), and nocturnal gastric drip feeding — prevents hypoglycemia and reduces metabolic derangements.

The critical phenotypic distinction between types Ia and Ib is that type Ib patients develop neutropenia and neutrophil dysfunction — causing recurrent bacterial infections, oral ulcers, and inflammatory bowel disease (IBD-like) — in addition to the metabolic phenotype shared with type Ia. Empagliflozin, an SGLT2 inhibitor repurposed from diabetes treatment, has dramatically improved neutropenia and IBD symptoms in GSD type Ib by reducing intracellular glucose-6-phosphate accumulation in neutrophils. This gene-specific therapy makes molecular genotyping essential: type Ia patients do not develop neutropenia and do not benefit from empagliflozin.

Empagliflozin — a diabetes drug repurposed for GSD type Ib — has transformed management of the neutropenia and IBD-like colitis that type Ib patients develop. This therapy is only indicated for type Ib (SLC37A4), not type Ia (G6PC).

Gene locus: G6PC (17q21.31) for type Ia, SLC37A4 (11q23.3) for type Ib

Type Ia vs. type Ib distinction determines whether neutropenia management and empagliflozin therapy are needed — a genotype-specific treatment decision that standard metabolic workup does not resolve.

Empagliflozin for type Ib neutropenia is a breakthrough — but is only indicated with confirmed SLC37A4 genotype

GSD type Ib patients accumulate 1,5-anhydroglucitol-6-phosphate (1,5-AG6P) in neutrophils, causing neutrophil dysfunction and neutropenia. Empagliflozin, by blocking renal glucose reabsorption, lowers circulating 1,5-AG levels and reduces neutrophil 1,5-AG6P accumulation — restoring neutrophil counts and function. Multiple case series demonstrate dramatic improvements in neutropenia, mucosal ulceration, and inflammatory bowel disease symptoms. This therapy is specific to the SLC37A4 translocase defect; G6PC-deficient (type Ia) patients do not accumulate 1,5-AG6P and do not benefit. Molecular genotyping identifies the appropriate candidates.

Hepatic adenomas develop in 50-75% of GSD-I patients — surveillance for malignant transformation requires lifelong imaging

Hepatocellular adenomas (HCA) are a major long-term complication of GSD-I, developing in the majority of patients by adulthood. While most HCA remain benign, malignant transformation to hepatocellular carcinoma (HCC) occurs — requiring regular hepatic imaging (ultrasound, MRI) and alpha-fetoprotein monitoring. Confirmed molecular GSD-I diagnosis ensures that the patient is enrolled in the appropriate hepatic surveillance protocol. Additionally, molecular diagnosis enables carrier testing for siblings and reproductive planning for affected adults.

Glycogen Storage Disease Type I — where the specific gene (G6PC vs. SLC37A4) determines whether the patient faces only metabolic challenges or also develops neutropenia, recurrent infections, and inflammatory bowel disease requiring additional targeted therapy.

Glycogen Storage Disease Type I

Type Ia vs. type Ib distinction determines whether neutropenia management and empagliflozin therapy are needed — a genotype-specific treatment decision that standard metabolic workup does not resolve.

Empagliflozin for type Ib neutropenia is a breakthrough — but is only indicated with confirmed SLC37A4 genotype

Hepatic adenomas develop in 50-75% of GSD-I patients — surveillance for malignant transformation requires lifelong imaging

Others in Metabolic

One test. A lifetime of answers.